Suzanne Lentzsch, Md

This study tests whether a combination of two drugs, teclistamab and daratumumab, can safely and effectively treat AL amyloidosis, a rare disease where abnormal proteins damage organs. The treatment lasts 6 months and involves 25 adults who have not received prior therapy. The ma…